What are the treatment options for non-muscle-invasive bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

The treatment of non–muscle-invasive bladder cancer (Ta, T1, carcinoma in situ [CIS]) begins with transurethral resection of bladder tumor (TURBT). Subsequent treatment is as follows:

  • Small-volume, low-grade Ta bladder cancer - An immediate single, postoperative dose of intravesical chemotherapy
  • Intermediate-risk bladder cancer (recurrent low grade, high volume low grade, high-grade Ta) – Intravesical chemotherapy or BCG
  • High-risk Ta, T1, and CIS urothelial carcinoma - Intravesical BCG
  • Persistent or recurrent high-risk disease - Repeat resection prior to additional intravesical therapy; consider cystectomy for high-risk disease

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!